Duchin K L, Singhvi S M, Willard D A, Migdalof B H, McKinstry D N
Clin Pharmacol Ther. 1982 Apr;31(4):452-8. doi: 10.1038/clpt.1982.59.
Captopril, an angiotensin-converting enzyme inhibitor with antihypertensive properties, was given by mouth and intravenously in 10-mg doses to five healthy subjects. After intravenous dosing, semilogarithmic plots of captopril blood levels : time showed a triexponential decay. Data were analyzed using an open three-compartment model. The average volume of distribution (Vd) was 0.2 l/kg for the central compartment and 2 l/kg for the elimination (beta) phase. The Vd at steady-state was 0.7 l/kg. The total body clearance of captopril averaged 0.8 l/kg/hr and the mean blood half-life during the beta phase was 1.9 hr. In the 0- to 96-hr urine, after intravenous and oral drug, excretion of radioactivity accounted for 87% and 61% of dose. In the 0- to 24-hr urine, averages of 38% (intravenous) and 24% (oral) of the doses were excreted as unchanged captopril. Absolute absorption of the radioactive oral dose was 71% and the absolute oral bioavailability of captopril was 62%.
卡托普利是一种具有降压特性的血管紧张素转换酶抑制剂,以10毫克剂量口服和静脉注射给予5名健康受试者。静脉给药后,卡托普利血药浓度与时间的半对数图显示为三指数衰减。使用开放三室模型分析数据。中央室的平均分布容积(Vd)为0.2升/千克,消除(β)相的Vd为2升/千克。稳态时的Vd为0.7升/千克。卡托普利的总体清除率平均为0.8升/千克/小时,β相期间的平均血药半衰期为1.9小时。静脉注射和口服药物后,在0至96小时尿液中,放射性排泄分别占给药剂量的87%和61%。在0至24小时尿液中,静脉注射和口服剂量的平均值分别有38%(静脉注射)和24%(口服)以原形卡托普利排泄。放射性口服剂量的绝对吸收率为71%,卡托普利的绝对口服生物利用度为62%。